Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Bertani

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Journal of Clinical Medicine|September 23, 2022
Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic ChoicesLorenzo Bertani
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issueLorenzo Bertani, Domenico Tricò
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 21, 2023
Management of inflammatory bowel disease in the elderly: A reviewPaula Sousa, Lorenzo Bertani, Cláudio Rodrigues
Alimentary Pharmacology & Therapeutics|September 5, 2020
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?Lorenzo Bertani, Luca Antonioli, Corrado Blandizzi
Alimentary Pharmacology & Therapeutics|October 29, 2020
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' replyLorenzo Bertani, Matteo Fornai, Luca Antonioli, et al.
Inflammatory Bowel Diseases|June 10, 2020
Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNFLorenzo Bertani, Francesco Costa, Brigida Barberio, et al.
Gastroenterology|July 21, 2020
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?Brigida Barberio, Fabiana Zingone, Lorenzo Bertani, et al.
Alimentary Pharmacology & Therapeutics|December 28, 2020
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' replyLorenzo Bertani, Daniela Pugliese, Domenico Tricò, et al.
Nutrients|April 30, 2021
Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions?Lorenzo Bertani, Davide Giuseppe Ribaldone, Massimo Bellini, et al.
Frontiers in Immunology|August 28, 2020
Inflammatory Bowel Diseases: It's Time for the Adenosine SystemLuca Antonioli, Matteo Fornai, Carolina Pellegrini, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Journal of Clinical Medicine|September 23, 2022
Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic ChoicesLorenzo Bertani
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issueLorenzo Bertani, Domenico Tricò
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 21, 2023
Management of inflammatory bowel disease in the elderly: A reviewPaula Sousa, Lorenzo Bertani, Cláudio Rodrigues
Alimentary Pharmacology & Therapeutics|September 5, 2020
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?Lorenzo Bertani, Luca Antonioli, Corrado Blandizzi
Alimentary Pharmacology & Therapeutics|October 29, 2020
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' replyLorenzo Bertani, Matteo Fornai, Luca Antonioli, et al.
Inflammatory Bowel Diseases|June 10, 2020
Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNFLorenzo Bertani, Francesco Costa, Brigida Barberio, et al.
Gastroenterology|July 21, 2020
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?Brigida Barberio, Fabiana Zingone, Lorenzo Bertani, et al.
Alimentary Pharmacology & Therapeutics|December 28, 2020
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' replyLorenzo Bertani, Daniela Pugliese, Domenico Tricò, et al.
Nutrients|April 30, 2021
Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions?Lorenzo Bertani, Davide Giuseppe Ribaldone, Massimo Bellini, et al.
Frontiers in Immunology|August 28, 2020
Inflammatory Bowel Diseases: It's Time for the Adenosine SystemLuca Antonioli, Matteo Fornai, Carolina Pellegrini, et al.
Pageof 9